Corcept Therapeutics
CORT
#2491
Rank
โ‚ฌ6.44 B
Marketcap
58,91ย โ‚ฌ
Share price
-4.45%
Change (1 day)
-9.17%
Change (1 year)

P/E ratio for Corcept Therapeutics (CORT)

P/E ratio as of November 2026 (TTM): 45.2

According to Corcept Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 45.1933. At the end of 2025 the company had a P/E ratio of 37.0.

P/E ratio history for Corcept Therapeutics from 2004 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202537.0-0.82%
202437.3
202221.44.74%
202120.4-28.21%
202028.495.05%
201914.6-29.07%
201820.628.6%
201716.0

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
40.8-9.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
29.6-34.58%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
39.5-12.55%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
44.8-0.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
139 207.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
13.2-70.84%๐Ÿ‡บ๐Ÿ‡ธ USA
MannKind Corp
MNKD
-31.3-169.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
-159-451.82%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
-683-1,610.30%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.